Alberta Investment Management Corp (AIMCo)’s Apogee Therapeutics APGE Stock Holding History

Alberta Investment Management Corp (AIMCo)’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.95M	Buy	+75,000	New	+$6.76M	0.06%	224

Other funds holding APGE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCP

Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

CCM

Chicago Capital Management Chicago, Illinois $112M AUM 76.54% 1-Year Est. Return

Alberta Investment Management Corp (AIMCo)'s APGE Position: Q2 2026 in Review

Alberta Investment Management Corp (AIMCo) opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 75,000 shares worth $9.95M. The stake represents 0.06% of the portfolio and ranks #224 among its holdings.

77 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Alberta Investment Management Corp (AIMCo) held 75,000 shares of Apogee Therapeutics worth $9.95M as of Q2 2026.
Apogee Therapeutics was a new Alberta Investment Management Corp (AIMCo) position in Q2 2026.
Apogee Therapeutics made up 0.06% of Alberta Investment Management Corp (AIMCo)'s portfolio in Q2 2026, its #224 holding.
77 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Alberta Investment Management Corp (AIMCo)'s 13F filing for Q2 2026, filed 6 Aug 2026.